ClinicalTrials.gg
CompletedNCT00539864Updated Jul 27, 2011Results posted

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

A Phase 3 interventional study of FluBlok Influenza Vaccination and TIV (Fluzone) Influenza Vaccination in Influenza, sponsored by Protein Sciences Corporation. Completed at 5 sites in United States. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-07-27.

Sponsored by Protein Sciences Corporation · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
50 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.

Enrollment
7th of 11
602 · median 606
Started
2007
with 1 other
Phase 3
3 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
3 of 11
Protein Sciences Corporation

Among the 11 studies testing FluBlok in Influenza, Human, this one is the 7th largest by enrollment, is one of 2 that started in 2007, is one of 3 in phase 3, and was the 3rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →

Where they have run

About FluBlok

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing FluBlok in Influenza, Human as a file.
02

Study summary

The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.

Read the detailed description

Annual influenza epidemics are associated with serious excess morbidity and mortality, particularly among the elderly. Licensed trivalent inactivated influenza vaccines (TIVs) have been shown to reduce hospitalization and death following influenza in this vulnerable population, but their efficacy is lower than that observed in younger, healthy populations. In addition, recent studies have questioned the level of effectiveness of TIV in the elderly, suggesting that cohort studies have overestimated the benefits of immunization with current TIV formulations in this age group. In view of these considerations, it is widely accepted that improved and alternative vaccines are needed for control of seasonal and pandemic influenza.

Currently available TIVs are prepared from viruses that are grown in embryonated hens' eggs. Alternative substrates for vaccine production are desirable in order to reduce the vulnerability of and to expand influenza vaccine supply. Recombinant DNA techniques allow for expression of the influenza hemagglutinin (rHA) by baculovirus vectors in insect cell cultures. Advantages of this technique include speed of production, absence of egg protein, and a highly purified product. Previous studies among healthy younger and older adults have confirmed that rHA vaccines are safe, well tolerated and immunogenic at dosages up to nine times higher than those contained in TIV. Dose-related increases in serum antibody levels after immunization also were observed.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Influenza
04

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50 to 64.
  • Females should be at least 2 years or sterile or practicing accepted form of (including: condom with spermicidal, licensed hormonal contraceptive, abstinence, IUD or monogamous relationship with a vasectomized partner).
  • Healthy, as determined by oral temperature \<100.0°F, medical history, and medical assessment w/ brief physical evaluation by RN (if indicated) based on medical history.
  • Able to understand and comply with planned study procedures.
  • Provides written prior to initiation of any study procedure.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to eggs or other vaccine components.
  • as a result of an underlying illness or treatment, or used anticancer chemotherapy or radiation therapy within the preceding 36 months.
  • Any other than localized prostate cancer, diagnosed or treated actively during the past 5 years. Exceptions: Subjects with a history of lymphoproliferative disorder at any time in their life will be excluded, while subjects with a history of localized nonmelanotic skin cancer that has been completely removed during the past 5 years may be eligible.
  • Long-term use of oral , parenteral steroids, or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (Nasal and topical steroids are allowed).
  • Diagnosis of or treatment for bipolar disorder, severe major depression, schizophrenia or other major psychotic disorder in the past 3 months that is associated with severely impaired judgment or cognition.
  • History of receiving immunoglobulin or other blood product within the 3 months prior to enrollment in this study.
  • Receipt of any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for ) prior to enrollment in this study.
  • Use of experimental vaccines or any influenza vaccine other than FluBlOk after May 31st 2007 for the 2008 Southern Hemisphere or 2007 to 2008 Northern hemisphere epidemic seasons.
  • History of severe reactions following immunization with influenza virus vaccines.
  • Moderate to severe acute illness or febrile illness (oral temperature greater than 100degreesF) within 1 week prior to vaccination.
  • Receipt of an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month prior to enrollment in this study, or expects to receive an experimental agent during study period.
  • Known active , , or infection.
  • History of alcohol or drug abuse in the last 5 years.
  • History of Guillain-Barré Syndrome.
  • Subject is not available for three (3) or more consecutive weeks during active influenza season.
  • Any acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe, interfere with the evaluation of responses, or render the subject unable to meet the requirements of the protocol. These conditions include, but are not limited to: history of significant renal impairment (dialysis and treatment for kidney disease, including diabetic and hypertensive kidney disease); subjects with diabetes mellitus, well-controlled with oral agents may enroll as long there has been no dosage increase within the past 6 months; insulin-dependent diabetes is excluded; cardiac insufficiency, if heart failure is present ( Functional Class III or IV); an arteriosclerotic event during the 6 months prior to enrollment (e.g., history of myocardial infarction, stroke, recanalization of femoral arteries, or )
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
602 participants (actual)

Study arms

  • Experimental
    FluBlok

    Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 135μg total

    Biological: FluBlok Influenza Vaccination

  • Active comparator
    TIV (Fluzone)

    Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 45μg total (Fluzone, sanofi pasteur)

    Biological: TIV (Fluzone) Influenza Vaccination

Interventions

  • 0.5mL dose for intramuscular injection

    Also known as: FluBlok, rHA, rHA0, recombinant hemagglutinin

  • BiologicalTIV (Fluzone) Influenza Vaccination

    0.5mL dose for intramuscular injection

    Also known as: Fluzone, TIV

06

What researchers measure

Primary outcomes

  1. Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)

    Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.

    Time frame: Reactogenicity days 0-7 following immunization; other AEs days 0-28 following immunization

Secondary outcomes

  1. Evaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.

    Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.

    Time frame: Day 0 and Day 28

  2. Percentage of Participants With Seroconversion

    Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization

    Time frame: Day 28 following immunization at Day 0

  3. Percentage of Participants With Seroprotection

    Percentage of participants with (HAI titer greater than or equal to 40) at Day 28

    Time frame: Day 28 following immunization at Day 0

07

Results

Posted Jul 27, 2011

Participant flow

Subjects 50 - \<64 years of age were screened in participating outpatient clinics for eligibility within 30 days of randomization during the 2007 influenza season.

Participant flow — Overall Study
MilestoneFluBlokTIV (Fluzone)
Started300302
Completed299300
Not completed12
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject11

Outcome measures

SecondaryEvaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.

Immunogenicity was assessed by measuring the difference in values in Hemagglutination-Inhibition Assay (HAI) titers in participants from Day 0 to Day 28, using Geometric Mean Titers (GMTs). The GMTs from the FluBlok and TIV groups were then compared.

Time frame:
Day 0 and Day 28
Reported as:
Geometric mean · HAI Titers
Evaluation and Comparison of Immunogenicity of FluBlok and TIV in Healthy Adults 50-64 Years of Age.
HAI TitersFluBlokTIV (Fluzone)
A/Solomon Islands (H1N1) - Day 028.71 (25.59 to 32.21)27.77 (25.07 to 30.76)
A/Solomon Islands (H1N1) - Day 28181.34 (159.61 to 206.02)139.74 (124.64 to 156.66)
A/Wisconsin (H3N2) - Day 018.57 (16.37 to 21.06)18.20 (16.07 to 20.62)
A/Wisconsin (H3N2) - Day 28105.41 (91.01 to 122.09)60.88 (53.58 to 69.18)
B/Malaysia - Day 048.49 (43.38 to 54.19)49.18 (43.77 to 55.25)
B/Malaysia - Day 28110.93 (100.07 to 122.97)116.03 (104.16 to 129.25)
PrimaryNumber of Participants With Reactogenicity (Solicited) Adverse Events (AEs)

Solicited reactogenicity events included injection site pain, bruising, erythema and swelling. Solicited systemic AEs included fatigue, chills, arthralgias, myalgias, headache and nausea.

Time frame:
Reactogenicity days 0-7 following immunization; other AEs days 0-28 following immunization
Reported as:
Number · participants
Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs)
participantsFluBlokTIV (Fluzone)
Fatigue4062
Chills1215
Arthralgias1519
Myalgia4063
Headache5963
Nausea1315
Injection Site Pain154165
Injection Site Bruising1614
Injection Site Erythema2425
Injection Site Swelling2530
SecondaryPercentage of Participants With Seroconversion

Percentage of participants with greater than or equal to a 4-fold rise in Hemagglutination-Inhibition Assay (HAI) titer over Day 0 at Day 28 following immunization

Time frame:
Day 28 following immunization at Day 0
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroconversion
Percentage of participantsFluBlokTIV (Fluzone)
A/Solomon Islands (H1N1)72 (66.8 to 77.2)66 (60.6 to 71.5)
A/Wisconsin (H3N2)61 (55.4 to 66.8)44 (38.0 to 69.2)
B/Malaysia41 (35.2 to 46.6)41 (35.5 to 46.8)
SecondaryPercentage of Participants With Seroprotection

Percentage of participants with (HAI titer greater than or equal to 40) at Day 28

Time frame:
Day 28 following immunization at Day 0
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroprotection
Percentage of participantsFluBlokTIV (Fluzone)
Influenza A/Solomon Islands (H1N1)96 (93.5 to 98.1)96 (92.8 to 97.7)
Influenza A/Wisconsin (H3N2)85 (80.8 to 89.1)75 (69.9 to 79.9)
Influenza B/Malaysia93 (89.5 to 95.6)94 (91.1 to 96.7)

Adverse events

Collected over All AEs - 28 days following immunization; SAEs for duration of influenza season.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FluBlok—1/300 (0.3%)4/300 (1.3%)
TIV (Fluzone)—0/302 (0%)9/302 (3%)
Most frequent serious events
Most frequent serious events
EventFluBlokTIV (Fluzone)
Vasovagal SyncopeCardiac disorders1/3000/302
Most frequent other events
Most frequent other events
EventFluBlokTIV (Fluzone)
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders4/3009/302

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)FluBlokTIV (Fluzone)Total
<=18 years000
Between 18 and 65 years300302602
>=65 years000
Age Continuous
Age Continuous(years)FluBlokTIV (Fluzone)Total
Mean55.9 ± 3.7155.7 ± 3.6455.8 ± 3.67
Sex: Female, Male
Sex: Female, Male(Participants)FluBlokTIV (Fluzone)Total
Female187192379
Male113110223
Region of Enrollment
Region of Enrollment(participants)FluBlokTIV (Fluzone)Total
United States300302602
08

Study locations

5 sites
  • Kaiser Permanente Pediatric Clinic - Fresno
    Fresno, California 93726, United States
  • Kaiser Permanente Pediatric Clinic - Hayward
    Hayward, California 94545, United States
  • Kaiser Permanente Pediatric Clinic - Roseville
    Roseville, California 95661, United States
  • Kaiser Permanente Pediatric Clinic - Sacramento
    Sacramento, California 95823, United States
  • Kaiser Permanente
    Honolulu, Hawaii 96814, United States
09

References and documents

Publications

  • Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28. PubMed 21277410 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 5, 2007
Start
Sep 2007
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jul 27, 2011
Last update
Jul 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00539864
Lead sponsor
Protein Sciences Corporation
First posted
Oct 5, 2007
Start date
Sep 2007
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jul 27, 2011
Last update
Jul 27, 2011

Study contacts

Roger Baxter, MD
principal investigator · Kaiser Permanenter Center for Vaccine Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluBlok

Start the discussion